COMMUNIQUÉS West-GlobeNewswire

Amneal to Participate in Upcoming Investor Conferences
02/12/2025
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will [...]
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
02/12/2025
Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in [...]
Genvor and Tuskegee University Announce Teaming Agreement to Advance Peptide Research and Sustainable Crop Protection Technologies
02/12/2025
Woodland, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced it has entered into a formal teaming agreement with [...]
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
02/12/2025
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano , a clinical-stage nanomedicine company, today announced new data demonstrating that [...]
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
02/12/2025
DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos [...]
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
02/12/2025
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, [...]
The Ensign Group Increases Operations in Arizona
02/12/2025
SAN JUAN CAPISTRANO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Grows Operations in Colorado
02/12/2025
SAN JUAN CAPISTRANO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Tacalyx Appoints Jean Engela as Chief Executive Officer to Spearhead Next Phase of Growth
02/12/2025
Berlin, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces the appointment of Jean [...]
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
02/12/2025
The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chain Clients to benefit from accelerated timelines, as well as reduced [...]
Ventyx Provides Clinical and Corporate Updates
02/12/2025
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD [...]
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
02/12/2025
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in [...]
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
02/12/2025
1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in [...]
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
02/12/2025
Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital [...]
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
02/12/2025
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment 1.5% mean weight change observed with Revita (n=17); [...]
Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia
02/12/2025
Deeply experienced industry leaders further strengthen Comanche’s leadership and expertise as it advances CBP-4888 as a potential global solution for sFlt1-mediated preterm preeclampsia CONCORD, Mass., Dec. 02, 2025 ( [...]
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
02/12/2025
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the [...]
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
02/12/2025
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study [...]
Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook
02/12/2025
VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) is pleased to provide a corporate update following its recently released Q3 financial results and [...]

Pages